• Home
  • Our Company
    • History
    • Ambition
    • Services
    • Group of companies
    • Partners
  • Quality Policy
    • Our Policy
    • Permissions & Certificates
  • Products
    • Portfolio >
      • Epinephrine Base
      • Epinephrine Bitartrate
      • Clenbuterol HCl
      • Scopolamine Base
      • Scopolamine Hydrobromide
      • Scopolamine Methylbromide
      • ... more Products
    • Portfolio TP USA
  • Team
    • Sales & Marketing
    • Logistics
    • Scientific & Regulatory
    • Administration
    • Management
    • TP USA
  • Contact
    • Germany
    • USA
    • Hong Kong
    • Singapore
  • Blog
TRANSOPHARM.COM
  • Home
  • Our Company
    • History
    • Ambition
    • Services
    • Group of companies
    • Partners
  • Quality Policy
    • Our Policy
    • Permissions & Certificates
  • Products
    • Portfolio >
      • Epinephrine Base
      • Epinephrine Bitartrate
      • Clenbuterol HCl
      • Scopolamine Base
      • Scopolamine Hydrobromide
      • Scopolamine Methylbromide
      • ... more Products
    • Portfolio TP USA
  • Team
    • Sales & Marketing
    • Logistics
    • Scientific & Regulatory
    • Administration
    • Management
    • TP USA
  • Contact
    • Germany
    • USA
    • Hong Kong
    • Singapore
  • Blog

Transo-Pharm establishes relationship with 22nd Century Group as their partner for Global Sales, Marketing, and Distribution of Pharmaceutical Grade Cannabinoid APIs

1/25/2023

0 Comments

 
Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry
​22nd Century Group, Inc., a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced filing of a U.S. Drug Master File (DMF) to the US Food & Drug Administration (FDA) for cannabidiol (CBD) API from GVB Biopharma, a 22nd Century Group Company. The submission (DMF 037727) demonstrates 22nd Century Group’s absolute commitment to supplying high quality pharmaceutical grade API to the pharmaceutical industry and OTC markets.

​Said James A. Mish, chief executive officer of 22nd Century, “GVB Biopharma is widely recognized for the quality and consistency of its Cannabinoid extracts and ingredients. We are now leveraging these capabilities with our DMF filing to meet the increasing regulatory demands of the supplements markets in the US and Europe, and in parallel it expands our reach to the pharmaceutical and OTC markets, where consistently regulated high quality ingredients are a requirement. Our compliance infrastructure will ensure that our customers consistently receive API that meets the appropriate quality standards.”

Additionally, 22nd Century and GVB Biopharma have entered into an agreement with Cannabinoid API Solutions (CAS) and Transo-Pharm for global sales, marketing, and distribution of GVB’s Cannabinoid APIs. With more than 35 years of industry experience as a leading global supplier of pharmaceutical grade APIs, Transo-Pharm is a well-established supplier and distributor of pharmaceutical APIs to a broad portfolio of branded and generic finished drug product manufacturers, including more than 75 current active ongoing development programs. Transo-Pharm is partnered with an extensive range of reputable multinational pharmaceutical companies, all of which will have immediate access to GVB’s cannabinoid APIs.

“The partnership with Transo-Pharm will accelerate opportunities to supply our APIs to the largest and most innovative pharmaceutical and consumer goods manufacturers in the world,” said Mish. “We estimate the Cannabinoid Derived Pharmaceutical market to be worth $1 billion in 2022 and growing, a trend we see accelerating as new entrants continue join the market. This partnership immediately provides us with the channel access and reach to support pharmaceutical programs worldwide as well as securing new opportunities in over-the-counter and consumer packaged goods spaces. Our regulated pharmaceutical grade ingredients supply chain will provide for the highest levels of quality, consistency and compliance across our entire customer base.”

About Transo-Pharm
Founded in 1987 and based in Germany and the US, Transo-Pharm has established a global reputation as a trusted supplier of active pharmaceutical ingredients (APIs). Transo-Pharm successfully connects suppliers and customers utilizing our experience, industry knowledge, marketing expertise and logistics capabilities. 

About 22nd Century Group, Inc.
22nd Century Group, Inc. is a leading biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Press release 22nd Century Group, Inc. 

xxii_century_transo-pharm-us_press_release.pdf
File Size: 102 kb
File Type: pdf
Download File

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Categories

    All
    Alkaloids
    Cannabinoids
    CBD
    CEP
    Chief Christmas Officers
    COVID 19
    CPhI
    DCAT
    Digoxin
    EDQM
    Epinephrine
    Estriol
    GMP
    Good Bye!
    Hapila
    Little Guy
    Logistics
    Nonivamide
    Partner
    Partnership
    Phyto
    Regulation
    Regulatory
    Safety
    Season Greetings
    Supply Chain
    Transo-Pharm US


    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    June 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    June 2020
    May 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019

    RSS Feed

Services

Sourcing
Sales
Development

Products

Portfolio
​US Portfolio

Company

History
Ambition
​Services
Group
Partners
​
Quality Policy 
​Certificates

Team

Sales & Marketing
Logistics
Scientific & Regulatory
Administration
​Management
​TP USA

Contact

Germany
Hong Kong
Singapore
USA
Sitemap
Support
German Site
Imprint / Legal
Data Privacy
Code Of Conduct
© COPYRIGHT 2020
​ALL RIGHTS RESERVED.

Picture
Picture
  • Home
  • Our Company
    • History
    • Ambition
    • Services
    • Group of companies
    • Partners
  • Quality Policy
    • Our Policy
    • Permissions & Certificates
  • Products
    • Portfolio >
      • Epinephrine Base
      • Epinephrine Bitartrate
      • Clenbuterol HCl
      • Scopolamine Base
      • Scopolamine Hydrobromide
      • Scopolamine Methylbromide
      • ... more Products
    • Portfolio TP USA
  • Team
    • Sales & Marketing
    • Logistics
    • Scientific & Regulatory
    • Administration
    • Management
    • TP USA
  • Contact
    • Germany
    • USA
    • Hong Kong
    • Singapore
  • Blog